The phenomenon that targeted therapy containing regimens are ineffective in pancreatic cancer while the same regimens have shown significant activity in other GI tumour entities is also known for anti-EGFR and anti-VEGF drugs (Kindler et al, 2010; Philip et al, 2010). This evidence concerns the gene EGFR and pancreatic neoplasm.